Leveraging Exosomes as the Next-Generation Bio-Shuttles: The Next Biggest Approach against Th17 Cell Catastrophe.
Leveraging Exosomes as the Next-Generation Bio-Shuttles: The Next Biggest Approach against Th17 Cell Catastrophe.
复制标题
DOI：
10.3390/ijms24087647
复制
发表时间：
2023-04-21
影响因子：
5.6
通讯作者：
Li X
中科院分区：
文献类型：
--
作者：
Samarpita S;Li X
近年来，临床级外泌体的推出正在迅速增加，因为它们代表了用于提供先进疗法和用于各种疾病诊断目的的新的强大方法。外泌体是膜结合的细胞外囊泡，其可以在健康和疾病的背景下充当细胞之间的生物信使。与实验室的药物载体相比，外泌体具有稳定性高、载药量多、免疫原性和毒性低等特点，在药物治疗中具有广阔的应用前景。刺激外泌体对无法治疗的目标进行药物治疗的努力令人鼓舞。目前，辅助性T（Th）17细胞被认为是建立自身免疫和几种遗传疾病的最突出因素。目前的报道已经表明靶向Th 17细胞的发育及其旁分泌分子白细胞介素（IL）-17的分泌的重要性。然而，目前的靶向方法表现出缺点，例如生产成本高、转化快、生物利用度差，并且重要的是，引起机会性感染，这最终阻碍了它们的临床应用。为了克服这一障碍，外泌体作为载体的潜在用途似乎是Th 17细胞靶向治疗的一种有前途的方法。本文从这一角度出发，对exosome的生物发生机制进行了综述，总结了exosome在多种疾病中的临床应用，分析了exosome作为药物载体的前景，并指出了目前面临的挑战，重点介绍了exosome在靶向Th 17细胞治疗疾病中的实际应用。我们进一步解码外来体生物工程的未来可能范围，靶向药物输送对Th 17细胞及其灾难。
In recent years, the launch of clinical-grade exosomes is rising expeditiously, as they represent a new powerful approach for the delivery of advanced therapies and for diagnostic purposes for various diseases. Exosomes are membrane-bound extracellular vesicles that can act as biological messengers between cells, in the context of health and disease. In comparison to several lab-based drug carriers, exosome exhibits high stability, accommodates diverse cargo loads, elicits low immunogenicity and toxicity, and therefore manifests tremendous perspectives in the development of therapeutics. The efforts made to spur exosomes in drugging the untreatable targets are encouraging. Currently, T helper (Th) 17 cells are considered the most prominent factor in the establishment of autoimmunity and several genetic disorders. Current reports have indicated the importance of targeting the development of Th17 cells and the secretion of its paracrine molecule, interleukin (IL)-17. However, the present-day targeted approaches exhibit drawbacks, such as high cost of production, rapid transformation, poor bioavailability, and importantly, causing opportunistic infections that ultimately hamper their clinical applications. To overcome this hurdle, the potential use of exosomes as vectors seem to be a promising approach for Th17 cell-targeted therapies. With this standpoint, this review discusses this new concept by providing a snapshot of exosome biogenesis, summarizes the current clinical trials of exosomes in several diseases, analyzes the prospect of exosomes as an established drug carrier and delineates the present challenges, with an emphasis on their practical applications in targeting Th17 cells in diseases. We further decode the possible future scope of exosome bioengineering for targeted drug delivery against Th17 cells and its catastrophe.
登录
查看更多内容
影响因子：
7.3
作者：
Andreu Z;Yáñez-Mó M
通讯作者：
Yáñez-Mó M
影响因子：
7.3
作者：
Bhaumik S;Basu R
通讯作者：
Basu R
影响因子：
3.8
作者：
Avdeev SN;Trushenko NV;Tsareva NA;Yaroshetskiy AI;Merzhoeva ZM;Nuralieva GS;Nekludova GV;Chikina SY;Gneusheva TY;Suvorova OA;Shmidt AE
通讯作者：
Shmidt AE
影响因子：
4.2
作者：
Cherney, Robert J.;Cornelius, Lyndon A. M.;Dhar, T. G. Murali
通讯作者：
Dhar, T. G. Murali
新黄芩素通过阻断 STAT3 信号传导抑制 Th17 细胞分化，从而恢复 Th17/Treg 比率
DOI：
10.3390/molecules28010018
发表时间：
2022-12-20
期刊：
Molecules (Basel, Switzerland)
影响因子：
--
作者：
Chen JY;Yang YJ;Ma XQ;Cao Q;Wei SS;Pan RR;Nan LH;Liu YJ;Cao Y;Tian XY;Deng S;Cheng ZX;Wang CJ;Chen T;Zheng YF;Huang MQ
通讯作者：
Huang MQ